Identification of hepatitis C virus transmission using a next-generation sequencing approach

Journal of Clinical Microbiology

Volumn 50, Issue 4, 2012, Pages 1461-1463

  Escobar Gutiérrez, Alejandro ^a   Vazquez Pichardo, Mauricio ^a   Cruz Rivera, Mayra ^a,b   Rivera Osorio, Pilar ^a   Carpio Pedroza, Juan Carlos ^a   Ruíz Pacheco, Juan Alberto ^a,c   Ruiz Tovar, Karina ^a,c   Vaughan, Gilberto ^a  

^a Instituto Nacional de Diagnostico y Referencia Epidemiologicos   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMPLICON; ARTICLE; CLINICAL ARTICLE; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HOST; HUMAN; INTRAHOST VIRAL GENETIC VARIATION; INTRAVENOUS DRUG ABUSE; MALE; MEXICO; NEXT GENERATION SEQUENCING; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS MORPHOLOGY; VIRUS TRANSMISSION;

ADULT; DRUG USERS; HEPACIVIRUS; HEPATITIS C; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MOLECULAR TYPING; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84858607120     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00005-12     Document Type: Article

References (19)

1. Advisory Council on the Misuse of Drugs. 2009. The primary prevention of hepatitis C among injecting drug users. Advisory Council on the Misuse of Drugs, London, United Kingdom.
2. Beerenwinkel N, Zagordi O. 2011. Ultra-deep sequencing for the analysis of viral populations. Curr. Opin. Virol. 1:413-418.
3. Boddiger D. 2010. Mexico eager to reduce demand for illicit drugs. Lancet 375:15-16.
4. Centers for Disease Control and Prevention. 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm. Rep. 47(RR-19):1-39.
5. Fischer GE, et al. 2010. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin. Infect. Dis. 51:267-273.
6. Fonseca-Coronado S, et al. 2012. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naive infected individuals. J. Clin. Microbiol. 50:281-287.
7. Hellard M, Sacks-Davis R, Gold J. 2009. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin. Infect. Dis. 49:561-573.
8. Katoh K, Toh H. 2008. Recent developments in the MAFFT multiple sequence alignment program. Brief. Bioinform. 9:286-298. (Pubitemid 351890825)
9. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17:107-115.
10. Martin NK, et al. 2011. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J. Hepatol. 54:1137-1144.
11. Martin NK, Vickerman P, Hickman M. 2011. Mathematical modelling of hepatitis C treatment for injecting drug users. J. Theor. Biol. 274:58-66.
12. Mendez-Sanchez N, et al. 2005. Prevalence of hepatitis C infection in a population of asymptomatic people in a checkup unit in Mexico City. Dig. Dis. Sci. 50:733-737. (Pubitemid 40558469)
13. Nelson PK, et al. 2011. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378:571-583.
14. Ramachandran S, Xia GL, Ganova-Raeva LM, Nainan OV, Khudyakov Y. 2008. End-point limiting-dilution real-time PCR assay for evaluation of hepatitis C virus quasispecies in serum: performance under optimal and suboptimal conditions. J. Virol. Methods 151:217-224.
15. Rivera-Lopez MR, Zavala-Mendez C, Arenas-Esqueda A. 2004. Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors. Gac. Med. Mex. 140:657-660. (In Spanish.) (Pubitemid 39655814)
16. Romero-Figueroa S, et al. 2012. Risk factors associated with hepatitis C virus infection in an urban population of the State of Mexico. Arch. Virol. 157:329-332.
17. Sosa-Jurado F, et al. 2010. Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. Virol. J. 7:18.
18. Tamura K, et al. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28:2731-2739.
19. Thompson ND, Perz JF, Moorman AC, Holmberg SD. 2009. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann. Intern. Med. 150:33-39.